Firms team up to develop peptide-based eye treatments

09/9/2013 | PharmaTimes (U.K.)

ThromboGenics and Bicycle Therapeutics agreed to collaborate in the development of treatments for diabetic macular edema and other eye conditions using the latter's bicyclic peptides. The deal entitles Bicycle to an upfront payment, milestone fees and sales royalties.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care